ThermiVa NYC - Expertise Matters

ThermiVa is an FDA-cleared, non-invasive radiofrequency treatment that gently heats vaginal and vulvar tissue to stimulate collagen production and tissue remodeling. Using a temperature-controlled handpiece, the Thermi RF+ device delivers consistent therapeutic heat to both external and internal tissue, promoting tightening, improved moisture, and enhanced sensation. The 30-minute in-office treatment requires no anesthesia, no incisions, and no downtime. Most patients describe the experience as a comfortable warming sensation similar to a warm stone massage.

ThermiVa is priced at $3,000 for the recommended series of three treatments ($1,000 per session) at The Dermatology & Laser Group. This represents competitive pricing for a board-certified dermatologist provider in Manhattan with over a decade of experience with this specific technology. Annual maintenance sessions are available at $1,000 per treatment to sustain long-term results.

No — ThermiVa is consistently described by patients as comfortable and even pleasant. The treatment uses temperature-controlled radiofrequency that feels like a gentle warming sensation. Unlike CO2 laser treatments that can cause significant discomfort, ThermiVa requires no topical anesthesia, no numbing cream, and no pain medication. Patients at our practice often describe the treatment as similar to a warm stone massage. You can return to all normal activities immediately after treatment, including exercise and intimacy.

Three treatments spaced approximately 2–3 weeks apart is the standard protocol. Most patients notice improvement after their first session, with progressive enhancement through the series as collagen remodeling continues over the following months. Results typically last 9–12 months, after which annual maintenance sessions help sustain improvements. Dr. Arash Akhavan customizes each treatment protocol based on individual concerns, anatomy, and goals during your initial consultation.

ThermiVa effectively addresses a wide range of feminine wellness concerns including vaginal laxity from childbirth or aging, external labial laxity, vaginal dryness and decreased lubrication, mild stress urinary incontinence (leaking with coughing, sneezing, or exercise), decreased sexual sensation, and difficulty achieving orgasm. The treatment is particularly popular among post-pregnancy women, perimenopausal and menopausal women, and breast cancer survivors who cannot use hormone-based therapies.

Most adult women who want to improve vaginal tightness, moisture, and sensation are good candidates, as are those with mild stress incontinence. Candidates include women who have completed childbearing (though it is safe before future pregnancies), perimenopausal and menopausal women experiencing tissue changes, breast cancer survivors who cannot use estrogen-based therapies, and women seeking non-surgical feminine rejuvenation without downtime. ThermiVa is safe for women of all skin types and tones. The treatment is not recommended for patients who are pregnant, have an active infection in the treatment area, or have an implanted electrical device such as a pacemaker. During your consultation at The Dermatology & Laser Group, Dr. Akhavan will evaluate your specific concerns to determine if ThermiVa is the right treatment for you.

ThermiVa and CO2 laser treatments work through fundamentally different mechanisms with different tradeoffs. ThermiVa uses radiofrequency energy that penetrates deeply into subdermal tissue (approximately 4mm), while CO2 lasers affect only the superficial mucosal layer (approximately 0.6mm). Key advantages of ThermiVa include zero pain versus moderate discomfort with CO2 lasers, no downtime versus 3–7 days of restricted activity, treatment of both internal and external tissue versus internal only, and no anesthesia required. ThermiVa also uniquely addresses stress incontinence and external labial laxity, which CO2 lasers cannot effectively treat.

Many patients report noticeable improvements after their very first session, particularly in vaginal tightness and moisture. The full benefits develop progressively as collagen remodeling occurs over the following 2–3 months after completing the three-treatment series. Tissue tightening continues to improve for up to 6 months post-treatment as new collagen fibers mature and strengthen. Results from the complete series typically last 9–12 months, with annual maintenance treatments helping to sustain and build upon initial improvements.

ThermiVa has an excellent safety profile with over a decade of clinical use worldwide. The treatment uses temperature-controlled radiofrequency with real-time thermal monitoring to ensure tissue is heated within a safe, therapeutic range. Side effects are minimal and may include mild warmth, slight pinkness, or temporary sensitivity in the treatment area that typically resolves within hours. There are no known reported cases of scarring, burns, or serious adverse events when performed by a qualified provider. At The Dermatology & Laser Group, Dr. Arash Akhavan uses the latest Thermi RF+ platform with enhanced safety monitoring.

Yes — ThermiVa has demonstrated meaningful improvement in mild to moderate stress urinary incontinence (SUI). By strengthening and tightening the tissue surrounding the urethra, ThermiVa can significantly reduce or eliminate stress incontinence episodes that occur with coughing, sneezing, laughing, or exercise. Published clinical data reports improvement rates of 67–78% in SUI symptoms following a three-treatment series. While ThermiVa is not a replacement for surgical intervention in severe incontinence cases, it offers a non-invasive first-line treatment option that many women find effective.